A new therapeutic antibody masks ErbB2 to its partners

被引：68

作者：

Badache, A ^{[1
]}

Hynes, NE ^{[1
]}

机构：

[1] Novartis Res Fdn, Friedrich Miescher Inst, CH-4002 Basel, Switzerland

来源：

CANCER CELL | 2004年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1535-6108(04)00088-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In cancer cells, the ErbB2 receptor tyrosine kinase can be activated in two ways: by overexpression or by ligand-mediated stimulation of another ErbB receptor. The ErbB2-targeting antibody trastuzumab (Herceptin) is used for treatment of metastatic breast cancer patients whose tumors overexpress ErbB2. A new structural study in this issue of Cancer Cell reveals how targeting ErbB2 with another antibody, pertuzumab (Omnitarg), prevents ligand-induced dimerization of ErbB2 with the other ErbB receptors. Pertuzumab's novel mode of action might offer additional therapeutic opportunities for treatment of tumors expressing ligand-activated ErbB2.

引用

页码：299 / 301

页数：3

共 9 条

[1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].

Agus, DB ;

Akita, RW ;

Fox, WD ;

Lewis, GD ;

Higgins, B ;

Pisacane, PI ;

Lofgren, JA ;

Tindell, C ;

Evans, DP ;

Maiese, K ;

Scher, HI ;

Sliwkowski, MX .

CANCER CELL, 2002, 2 (02) :127-137

[2] An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors [J].

Burgess, AW ;

Cho, HS ;

Eigenbrot, C ;

Ferguson, KM ;

Garrett, TPJ ;

Leahy, DJ ;

Lemmon, MA ;

Sliwkowski, MX ;

Ward, CW ;

Yokoyama, S .

MOLECULAR CELL, 2003, 12 (03) :541-552

[3] Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J].

Cho, HS ;

Mason, K ;

Ramyar, KX ;

Stanley, AM ;

Gabelli, SB ;

Denney, DW ;

Leahy, DJ .

NATURE, 2003, 421 (6924) :756-760

[4] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

[5] The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors [J].

Garrett, TPJ ;

McKern, NM ;

Lou, MZ ;

Elleman, TC ;

Adams, TE ;

Lovrecz, GO ;

Kofler, M ;

Jorissen, RN ;

Nice, EC ;

Burgess, AW ;

Ward, CW .

MOLECULAR CELL, 2003, 11 (02) :495-505

[6] ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling [J].

GrausPorta, D ;

Beerli, RR ;

Daly, JM ;

Hynes, NE .

EMBO JOURNAL, 1997, 16 (07) :1647-1655

[7] The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation [J].

Holbro, T ;

Beerli, RR ;

Maurer, F ;

Koziczak, M ;

Barbas, CF ;

Hynes, NE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (15) :8933-8938

[8]

Molina MA, 2001, CANCER RES, V61, P4744

[9] Untangling the ErbB signalling network [J].

Yarden, Y ;

Sliwkowski, MX .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (02) :127-137

← 1 →